MindMed adds a psychedelics therapy expert to its LSD research program.
Entheon Biomedical
Company Brief
Entheon Biomedical seeks to research, develop, patent, and distribute psilocybin and DMT based medicines and treatments for those suffering from substance-abuse disorders.This under-serviced market was valued at US$ 13.22 Billion in 2016, and is expected to grow to US$ 27.91 Billion by 2025.
Highlights
Related Articles
4 Palliative Canadians approved for end of life psilocybin therapy through section 56(1) ; First legal medical exemptions for psilocybin in Canada since 1970s
LEGAL use of psilocybin in Canada for the first time in nearly 50 years.
TSI EDITOR |
2020-08-05
Mindleap Health™ Expands its Digital Mental Health Programs for Addiction, Psychedelic Integration and Holistic Wellness
Mydecine's Vancouver-based affiliate, Mindleap Health™ is adding three digital therapy programs.
TSI EDITOR |
2020-08-04
Going To War For Legal Psychedelic Drugs
The need for the medicinal benefits of psychedelic drugs is producing unlikely allies.
TSI EDITOR |
2020-08-04
Novamind Closes the Acquisition of Cedar Psychiatry, a Leading Psychedelic Therapy Organization in the U.S.
Novamind acquires Utah-based Cedar Psychiatry and Cedar Clinical Research for CAD$3.05 million.
TSI EDITOR |
2020-07-31
Palliative Canadians endure punishing waits while Health Minister delays approval of Psilocybin mushrooms; TheraPsil expands effort to Ontario
More pressure on Ottawa to move forward on legalization of psilocybin.
TSI EDITOR |
2020-07-30
Latest Stories
NEW BULL MARKET ALERT
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now